Ocumetics Technology is trading 7.14% up at CA$0.45 after its first-in-human Group One clinical patients reached the 12-month follow-up milestone on September 17, 2026.
- Examinations have commenced, with results expected to be released shortly.
- Earlier follow-ups showed encouraging visual outcomes and safety results.
- No specific results-release time or analyst reaction was provided.